We reaffirm our Neutral recommendation for therapeutic and diagnostic devices maker AngioDynamics (NASDAQ:ANGO) following its second-quarter fiscal 2012 results. The company’s adjusted earnings of 13 cents a share beat the Zacks Consensus Estimate by a penny. Revenues climbed 9% year over year to $58.1 million, topping the Zacks Consensus Estimate of $56 million.
However, profits tanked 29% year over year on account of charges associated with CEO departure and the closure of the company’s U.K. … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here